Long COVID Symptomatology After 12 Months and Its Impact on Quality of Life According to Initial Coronavirus Disease 2019 Disease Severity
-
- Aurélie Fischer
- Deep Digital Phenotyping Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen , Luxembourg
-
- Lu Zhang
- Bioinformatics Platform, Luxembourg Institute of Health , Strassen , Luxembourg
-
- Abir Elbéji
- Deep Digital Phenotyping Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen , Luxembourg
-
- Paul Wilmes
- Luxembourg Center for Systems Biomedicine, University of Luxembourg, Belvaux , Luxembourg
-
- Pauline Oustric
- Association “Après J20” , Lucé , France
-
- Therese Staub
- Service National des Maladies Infectieuses, Centre Hospitalier de Luxembourg , Luxembourg , Luxembourg
-
- Petr V Nazarov
- Bioinformatics Platform, Luxembourg Institute of Health , Strassen , Luxembourg
-
- Markus Ollert
- Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette , Luxembourg
-
- Guy Fagherazzi
- Deep Digital Phenotyping Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen , Luxembourg
書誌事項
- 公開日
- 2022-08-01
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.1093/ofid/ofac397
- 公開者
- Oxford University Press (OUP)
説明
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>“Long COVID” is characterized by a variety of symptoms and an important burden for affected people. Our objective was to describe long COVID symptomatology according to initial coronavirus disease 2019 (COVID-19) severity.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Predi-COVID cohort study participants, recruited at the time of acute COVID-19 infection, completed a detailed 12-month symptom and quality of life questionnaire. Frequencies and co-occurrences of symptoms were assessed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among the 289 participants who fully completed the 12-month questionnaire, 59.5% reported at least 1 symptom, with a median of 6 symptoms. Participants with an initial moderate or severe acute illness declared more frequently 1 or more symptoms (82.6% vs 38.6%, P < .001) and had on average 6.8 more symptoms (95% confidence interval, 4.18–9.38) than initially asymptomatic participants who developed symptoms after the acute infection. Overall, 12.5% of the participants could not envisage coping with their symptoms in the long term. Frequently reported symptoms, such as neurological and cardiovascular symptoms, but also less frequent ones such as gastrointestinal symptoms, tended to cluster.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Frequencies and burden of symptoms present 12 months after acute COVID-19 infection increased with the severity of the acute illness. Long COVID likely consists of multiple subcategories rather than a single entity. This work will contribute to the better understanding of long COVID and to the definition of precision health strategies.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trials Registration</jats:title> <jats:p>NCT04380987.</jats:p> </jats:sec>
収録刊行物
-
- Open Forum Infectious Diseases
-
Open Forum Infectious Diseases 9 (8), ofac397-, 2022-08-01
Oxford University Press (OUP)